Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: European Myeloma Network (EMN) Sample Project
A European Myeloma Network study evaluating treatment options for multiple myeloma and related plasma cell disorders is currently recruiting…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma [NA]
Clinical trial update shows a study evaluating early palliative care for patients with multiple myeloma and aggressive lymphoma is currently…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma [Phase 1, Phase 2]
Ongoing Phase 1/2 clinical trial evaluating mezigdomide in combination with elranatamab for relapsed/refractory multiple myeloma; the study …
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
This document reports a prospective observational study called PREAMBLE in multiple myeloma. It is sponsored by Bristol-Myers Squibb and is …
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma [Phase 2]
Phase 2 clinical trial assessing lenalidomide and CC-486 with radiation therapy in patients with plasmacytoma; the study is currently active…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Clinical trial update describing a follow-up protocol for individuals previously enrolled in CAR-T cell studies, detailing a gene therapy fo…
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma [NA]
This clinical trial update describes ongoing recruitment for a non-chemotherapeutic intervention study intended to improve quality of life a…
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: Universal CAR-T Cell Therapy for MM [NA]
A clinical trial is recruiting for a universal CAR-T cell therapy to treat multiple myeloma, including relapsed and refractory disease. The …
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: Collection of Samples and Clinical Data From Patients With Amyloid Diseases
This clinical trial update notes ongoing recruitment to collect samples and clinical data from patients with amyloid diseases, including tho…
-
CLINICAL_TRIALS other · 2025-12-01Clinical Trial Update: A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies [Phase 1]
This document reports a Phase 1 clinical trial of BL-M24D1 in patients with relapsed or refractory multiple myeloma and other hematologic ma…
-
EMA approval · 2025-11-28EMA Authorised: Talvey (talquetamab) — Janssen-Cilag International N.V.
The European Medicines Agency authorised Talvey (talquetamab) for the treatment of multiple myeloma, with conditional approval and orphan me…
-
EMA approval · 2025-11-28EMA Authorised: Kyprolis (carfilzomib) — Amgen Europe B.V.
The European Medicines Agency authorised Kyprolis (carfilzomib) for the treatment of multiple myeloma. The decision was made on 14 December …
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma [Phase 1]
Phase 1 study evaluating belantamab mafodotin plus standard of care in newly diagnosed multiple myeloma. The trial is currently ACTIVE_NOT_R…
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma [Phase 2]
Phase 2 trial evaluating isatuximab, dexamethasone, and lenalidomide in ultra-frail patients with multiple myeloma and plasma cell leukemia,…
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: Mozobil for Autologous Hematopoietic Stem Cell Transplantation [Phase 2]
Phase 2 clinical trial update for Mozobil (plerixafor) in autologous hematopoietic stem cell transplantation, enrolling patients with multip…
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: Effects of a Resistance Physical Exercise Program in Multiple Myeloma Patients [NA]
This is a clinical trial update describing a resistance physical exercise program for patients with multiple myeloma; the study is currently…
-
EMA withdrawal · 2025-11-27EMA Lapsed: Celdoxome pegylated liposomal (doxorubicin hydrochloride) — Baxter Holding B.V.
EMA notes that the marketing authorization for Celdoxome pegylated liposomal doxorubicin hydrochloride has lapsed, covering breast cancer, o…
-
CLINICAL_TRIALS trial_result · 2025-11-26Clinical Trial Update: Covid-19 Vaccine Responsiveness in MM and Waldenstrom
Completed clinical trial update examining how patients with multiple myeloma and Waldenström macroglobulinemia respond to COVID-19 vaccinati…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration [Phase 1]
A Phase 1 clinical trial evaluating dual-target BCMA-CD19 CAR-T cell therapy for relapsed or refractory multiple myeloma with extramedullary…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
This clinical trial entry outlines PROMISE, a study aimed at predicting progression to multiple myeloma in a high-risk screened population. …
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma [Phase 1]
Phase 1 clinical trial evaluating an allogeneic umbilical cord blood–derived dual-targeting BCMA/CD19 CAR-T therapy for relapsed/refractory …
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma [EARLY_Phase 1]
An early-phase 1 clinical trial evaluating a dual-target CAR-T therapy (CAR19-BCMA) for relapsed/refractory multiple myeloma is currently re…
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients
A completed non-interventional study assessing Kyprolis in combination with Revlimid and dexamethasone, or dexamethasone alone, or with Darz…
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma [Phase 2]
This clinical trial update outlines the Phase 2 ELDORADO study, comparing Elranatamab versus Daratumumab each in combination with RVd Lite, …
-
CLINICAL_TRIALS trial_result · 2025-11-24Clinical Trial Update: A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial (PCD) [Phase 2]
A multicenter open-label Phase II study evaluating pomalidomide, cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma…